Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(66.7%)

N/A

1(33.3%)

3Total

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07385989Phase 2Not Yet Recruiting

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

Role: lead

NCT05680038Unknown

Penpulimab in Maintenance Therapy in Lymphoma

Role: lead

NCT05241132Phase 2Unknown

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Role: lead

NCT05173467Not ApplicableUnknown

Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor

Role: lead

NCT03892252Completed

Characteristics of Gut Microbiota in Patients With Colon Cancer of Different Traditional Chinese Medicine Syndromes

Role: lead

All 5 trials loaded